Back to Journals » Vascular Health and Risk Management » Volume 14

Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance

Authors Shunmoogam N, Naidoo P, Chilton R

Received 10 February 2018

Accepted for publication 12 April 2018

Published 18 June 2018 Volume 2018:14 Pages 137—143


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Konstantinos Tziomalos

Nelusha Shunmoogam,1 Poobalan Naidoo,1 Robert Chilton2

1Sanofi, Midrand, South Africa; 2Department of Medicine, Division of Cardiology and Interventional Cardiology, University of Texas Health Science Center at San Antonia, San Antonia, TX, USA

Abstract: Paraoxonase-1 (PON1) is a high-density lipoprotein-associated esterase and is speculated to play a role in several human diseases including diabetes mellitus and atherosclerosis. Low PON1 activity has been associated with increased risk of major cardiovascular events, therefore a variety of studies have been conducted to establish the cardioprotective properties and clinical relevance of PON1. The major aim of this review was to highlight the important studies and to subsequently assess if PON1 has clinical relevance. A review of the literature showed that there is currently insufficient data to suggest that PON1 has clinical relevance. It is our opinion that robust studies are required to clarify the clinical relevance of PON1.

Keywords: antioxidant, inflammation, atherosclerosis, cardiovascular disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]